Abstract
We present the case of a woman infected with the HIV type 1, controlled with highly active antiretroviral therapy. In the meantime, she developed a severe perianal disease, with complex fistulae and chronic anal fissures. After developing a severe chronic diarrhea, a total ileocolonoscopy with biopsies was performed, showing multiple ileal and segmental colonic erosions. Histology favoured a Crohn’s disease diagnosis. Despite the limited experience of anti-tumour necrosis factor agents in the HIV-infected population, infliximab was started in this patient, due to her severe and symptomatic Crohn’s disease, with a controlled HIV infection. No side effects were reported and her bowel movements and perianal disease improved right after induction regimen with infliximab. 1 year after starting this therapy she is in clinical and endoscopic remission. The CD4+ T-cell count remained stable, the HIV-RNA undetectable and no opportunistic infections were reported during follow-up period. Data concerning the use of anti-tumour necrosis factor drugs is limited in patients with both inflammatory bowel disease and HIV infection. Only three cases of Crohn’s disease and concomitant HIV infection treated with infliximab were reported in the literature. This case report might help future decisions in patients with a similar clinical situation.
Similar content being viewed by others
References
Béltran B, Nos P, Bastida G, et al. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn’s disease. Gut. 2006;55:670–1.
Habib SF, Hasan MZ, Salam I. Infliximab therapy for HIV positive Crohn’s disease: a case report. J Crohns Colitis. 2009;3:302–4.
Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74:974–80.
Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.
Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Annn Rheum Dis. 2008;67:710–2.
Nakamura M, Abrouk M, Farahnik B, et al. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018;101:38–42.
Almoallim H, Jali I, Wali G. Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia. Joint Bone Spine. 2013;80:426–8.
Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine. 2007;74:197–200.
Filippi J, Roger PM, Schneider SM, et al. Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med. 2006;166:1783–4.
Gaylis NB. Long term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol. 2012;18(3):153–4.
Funding
No funding was received for this submission;
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have no conflicts of interest regarding this submission;
Informed consent
Patient’s informed written consent was obtained before submitting the paper.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rafael, M.A., Lourenço, L.C., Oliveira, A.M. et al. Successful treatment of severe perianal Crohn’s disease with infliximab in an HIV-positive patient. Clin J Gastroenterol 12, 583–587 (2019). https://doi.org/10.1007/s12328-019-00992-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-019-00992-w